Takeda inks sweet $1.2B+ deal with Kumquat for immuno-oncology program

Takeda is offering Kumquat Biosciences the chance to make more than $1.2 billion biobucks in a new exclusive pact that centers around an unnamed immuno-oncology small molecule inhibitor.